医学
PCSK9
剩余风险
前蛋白转化酶
他汀类
可欣
药理学
冠状动脉疾病
动脉粥样硬化性心血管疾病
药物治疗
冲程(发动机)
内科学
药品
脂蛋白
重症监护医学
心脏病学
以兹提米比
疾病
胆固醇
脂蛋白(a)
低密度脂蛋白受体
机械工程
工程类
作者
Jennifer Hardy,Stephanie Niman,Rebecca F. Goldfaden,Majdi Ashchi,Mohannad Bisharat,Jessica Huston,Heather Hartmann,Rushab Choksi
标识
DOI:10.1007/s40256-021-00499-1
摘要
Patients with genetically associated elevated lipoprotein(a) [Lp(a)] levels are at greater risk for coronary artery disease, heart attack, stroke, and peripheral arterial disease. To date, there are no US FDA-approved drug therapies that are designed to target Lp(a) with the goal of lowering the Lp(a) level in patients who have increased risk. The American College of Cardiology (ACC) has provided guidelines on how to use traditional lipid profiles to assess the risk of atherosclerotic cardiovascular disease (ASCVD); however, even with the emergence of statin add-on therapies such as ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, some populations with elevated Lp(a) biomarkers remain at an increased risk for cardiovascular (CV) disease. Residual CV risk has led researchers to inquire about how lowering Lp(a) can be used as a potential preventative therapy in reducing CV events. This review aims to present and discuss the current clinical and scientific evidence pertaining to pelacarsen.
科研通智能强力驱动
Strongly Powered by AbleSci AI